Subcortical and cortical gray matter differences between Kraepelinian and non-Kraepelinian schizophrenia patients identified using voxel-based morphometry

Psychiatry Research - Neuroimaging

Volumn 184, Issue 1, 2010, Pages 16-22

  Molina, Vicente ^a   Hernández, Juan A ^b   Sanz, Javier ^c   Paniagua, Juan C ^a   Hernández, Ana I ^a   Martín, Carmen ^a   Matías, Juan ^a   Calama, Julia ^a   Bote, Berta ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSIDAD REY JUAN CARLOS   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Caudate; Kraepelinian; Putamen; Schizophrenia; Thalamus; Voxel based morphometry

Indexed keywords

ADULT; ARTICLE; BRAIN REGION; BRAIN SIZE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CORPUS STRIATUM; FEMALE; FRONTAL CORTEX; GRAY MATTER; HUMAN; LIMBIC CORTEX; MALE; MORPHOMETRICS; OCCIPITAL CORTEX; PRIORITY JOURNAL; PUTAMEN; SCHIZOPHRENIA; THALAMUS;

ADULT; BRAIN MAPPING; CEREBRAL CORTEX; FEMALE; HUMANS; IMAGING, THREE-DIMENSIONAL; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 77956960020     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2010.06.006     Document Type: Article

References (64)

1. Afifi A.K. Basal ganglia: functional anatomy and physiology. Part 2. Journal of Child Neurology 1994, 9:352-361.
2. Ashburner J., Friston K.J. Unified segmentation. Neuroimage 2005, 26:839-851.
3. Ballmaier M., Schlagenhauf F., Toga A.W., Gallinat J., Koslowski M., Zoli M., Hojatkashani C., Narr K.L., Heinz A. Regional patterns and clinical correlates of basal ganglia morphology in non-medicated schizophrenia. Schizophrenia Research 2008, 106(2-3):140-147.
4. Braff D.L., Heaton R., Kuck J., Cullum M., Moranville J., Grant I., Zisook S. The generalized pattern of neuropsychological deficits in outpatients with chronic schizophrenia with heterogeneous Wisconsin Card Sorting Test results. Archives of General Psychiatry 1991, 48:891-898.
5. Buchsbaum M.S., Wu J.C., DeLisi L.E., Holcomb H.H., Hazlett E., Cooper Langston K., Kessler R. Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. Biological Psychiatry 1987, 22:479-494.
6. Buchsbaum M.S., Shihabuddin L., Hazlett E.A., Schroder J., Haznedar M.M., Powchik P., Spiegel-Cohen J., Wei T., Singer M.B., Davis K.L. Kraepelinian and non-Kraepelinian schizophrenia subgroup differences in cerebral metabolic rate. Schizophrenia Research 2002, 55:25-40.
7. Buchsbaum M.S., Shihabuddin L., Brickman A.M., Miozzo R., Prikryl R., Shaw R., Davis K. Caudate and putamen volumes in good and poor outcome patients with schizophrenia. Schizophrenia Research 2003, 64:53-62.
8. Butler P.D., Schechter I., Zemon V., Schwartz S.G., Greenstein V.C., Gordon J., Schroeder C.E., Javitt D.C. Dysfunction of early-stage visual processing in schizophrenia. American Journal of Psychiatry 2001, 158:1126-1133.
9. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry 1994, 151:1430-1436.
10. Corson P.W., Nopoulos P., Andreasen N.C., Heckel D., Arndt S. Caudate size in first-episode neuroleptic-naive schizophrenic patients measured using an artificial neural network. Biological Psychiatry 1999, 46:712-720.
11. Davatzikos C., Shen D., Gur R.C., Wu X., Liu D., Fan Y., Hughett P., Turetsky B.I., Gur R.E. Whole-brain morphometric study of schizophrenia revealing a spatially complex set of focal abnormalities. Archives of General Psychiatry 2005, 62:1218-1227.
12. Davis K.L., Buchsbaum M.S., Shihabuddin L., Spiegel-Cohen J., Metzger M., Frecska E., Keefe R.S., Powchik P. Ventricular enlargement in poor-outcome schizophrenia. Biological Psychiatry 1998, 43:783-793.
13. DeLisi L.E., Holcomb H.H., Cohen R.M., Pickar D., Carpenter W., Morihisa J.M., King A.C., Kessler R., Buchsbaum M.S. Positron emission tomography in schizophrenic patients with and without neuroleptic medication. Journal of Cerebral Blood Flow and Metabolism 1985, 5:201-206.
14. DeLisi L.E., Sakuma M., Ge S., Kushner M. Association of brain structural change with the heterogeneous course of schizophrenia from early childhood through five years subsequent to a first hospitalization. Psychiatry Research: Neuroimaging 1998, 84:75-88.
15. DeLisi L.E., Sakuma M., Maurizio A.M., Relja M., Hoff A.M. Cerebral ventricular change over the first 10years after the onset of schizophrenia. Psychiatry Research: Neuroimaging 2004, 130:57-70.
16. Desco M., Gispert J., Reig S., Sanz J., Pascau J., Sarramea F., Benito C., Santos A., Palomo T., Molina V. Cerebral metabolic patterns in chronic and recent-onset schizophrenia. Psychiatry Research: Neuroimaging 2003, 122:125-135.
17. Dorph-Petersen K.A., Pierri J.N., Perel J.M., Sun Z., Sampson A.R., Lewis D.A. The influence of chronic exposure to antipsychotic medications on brain size before and after tissue fixation: a comparison of haloperidol and olanzapine in macaque monkeys. Neuropsychopharmacology 2005, 30:1649-1661.
18. Dorph-Petersen K.A., Pierri J.N., Wu Q., Sampson A.R., Lewis D.A. Primary visual cortex volume and total neuron number are reduced in schizophrenia. Journal Comprehensive Neurology 2007, 501:290-301.
19. First M.B., Spitzer R.L., Gibbon M., Williams J.B. Structured Clinical Interview 1997, American Psychiatric Press, Washington.
20. Friston K.J. Introduction: experimental design and statistical parametric mapping. Human Brain Function 2003, Academic Press. 2nd ed. R.S.J. Frackowiak, K.J. Friston, C. Frith, R. Dolan, K.J. Friston, C.J. Price (Eds.).
21. Glenthoj A., Glenthoj B.Y., Mackeprang T., Pagsberg A.K., Hemmingsen R.P., Jernigan T.L., Baare W.F. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Research 2007, 154:199-208.
22. Goldman-Rakic P.S., Selemon L.D. New frontiers in basal ganglia research. Introduction. Trends in Neurosciences 1990, 13:241-244.
23. Grahn J.A., Parkinson J.A., Owen A.M. The cognitive functions of the caudate nucleus. Progress Neurobiology 2008.
24. Hardoy M.C., Carta M.G., Catena M., Hardoy M.J., Cadeddu M., Dell'Osso L., Hugdahl K., Carpiniello B. Impairment in visual and spatial perception in schizophrenia and delusional disorder. Psychiatry Research 2004, 127:163-166.
25. Ho B.C., Andreasen N.C., Nopoulos P., Arndt S., Magnotta V., Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Archives of General Psychiatry 2003, 60:585-594.
26. Hollingshead A., Frederick R. Social stratification and psychiatric disorders. American Social Reviews 1953, 18:163-189.
27. Honea R., Crow T.J., Passingham D., Mackay C.E. Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. American Journal of Psychiatry 2005, 162:2233-2245.
28. Keefe R.S., Mohs R.C., Davidson M., Losonczy M.F., Silverman J.M., Lesser J.C., Horvath T.B., Davis K.L. Kraepelinian schizophrenia: a subgroup of schizophrenia?. Psychopharmacol Bulletin 1988, 24:56-61.
29. Keefe R.S., Frescka E., Apter S.H., Davidson M., Macaluso J.M., Hirschowitz J., Davis K.L. Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. American Journal of Psychiatry 1996, 153:806-811.
30. Keshavan M.S., Rosenberg D., Sweeney J.A., Pettegrew J.W. Decreased caudate volume in neuroleptic-naive psychotic patients. American Journal of Psychiatry 1998, 155:774-778.
31. Konopaske G.T., Dorph-Petersen K.A., Sweet R.A., Pierri J.N., Zhang W., Sampson A.R., Lewis D.A. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biological Psychiatry 2008, 63:759-765.
32. Koo M.S., Levitt J.J., McCarley R.W., Seidman L.J., Dickey C.C., Niznikiewicz M.A., Voglmaier M.M., Zamani P., Long K.R., Kim S.S., Shenton M.E. Reduction of caudate nucleus volumes in neuroleptic-naive female subjects with schizotypal personality disorder. Biological Psychiatry 2006, 60:40-48.
33. Kubicki M., Shenton M.E., Salisbury D.F., Hirayasu Y., Kasai K., Kikinis R., Jolesz F.A., McCarley R.W. Voxel-based morphometric analysis of gray matter in first episode schizophrenia. Neuroimage 2002, 17:1711-1719.
34. Levitt J.J., McCarley R.W., Dickey C.C., Voglmaier M.M., Niznikiewicz M.A., Seidman L.J., Hirayasu Y., Ciszewski A.A., Kikinis R., Jolesz F.A., Shenton M.E. MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder. American Journal of Psychiatry 2002, 159:1190-1197.
35. Levitt J.J., Westin C.F., Nestor P.G., Estepar R.S., Dickey C.C., Voglmaier M.M., Seidman L.J., Kikinis R., Jolesz F.A., McCarley R.W., Shenton M.E. Shape of caudate nucleus and its cognitive correlates in neuroleptic-naive schizotypal personality disorder. Biological Psychiatry 2004, 55:177-184.
36. Lieberman J.A., Tollefson G.D., Charles C., Zipursky R., Sharma T., Kahn R.S., Keefe R.S., Green A.I., Gur R.E., McEvoy J., Perkins D., Hamer R.M., Gu H., Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry 2005, 62:361-370.
37. Manoach D.S. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophrenia Research 2003, 60:285-298.
38. Mechelli A., Price C.J., Friston K.J., Ashburner J. Voxel-based morphometry of the human brain: methods and applications. Current Medical Imaging Reviews 2005, 105-113.
39. Meda S.A., Giuliani N.R., Calhoun V.D., Jagannathan K., Schretlen D.J., Pulver A., Cascella N., Keshavan M., Kates W., Buchanan R., Sharma T., Pearlson G.D. A large scale (N=400) investigation of gray matter differences in schizophrenia using optimized voxel-based morphometry. Schizophrenia Research 2008, 101:95-105.
40. Meisenzahl E.M., Koutsouleris N., Bottlender R., Scheuerecker J., Jager M., Teipel S.J., Holzinger S., Frodl T., Preuss U., Schmitt G., Burgermeister B., Reiser M., Born C., Moller H.J. Structural brain alterations at different stages of schizophrenia: a voxel-based morphometric study. Schizophrenia Research 2008, 104:44-60.
41. Mitelman S.A., Buchsbaum M.S. Very poor outcome schizophrenia: clinical and neuroimaging aspects. International Reviews on Psychiatry 2007, 19:345-357.
42. Mitelman S.A., Shihabuddin L., Brickman A.M., Hazlett E.A., Buchsbaum M.S. MRI assessment of gray and white matter distribution in Brodmann's areas of the cortex in patients with schizophrenia with good and poor outcomes. American Journal of Psychiatry 2003, 160:2154-2168.
43. Mitelman S.A., Brickman A.M., Shihabuddin L., Newmark R.E., Hazlett E.A., Haznedar M.M., Buchsbaum M.S. A comprehensive assessment of gray and white matter volumes and their relationship to outcome and severity in schizophrenia. Neuroimage 2007, 37:449-462.
44. Mitelman S.A., Canfield E.L., Chu K.W., Brickman A.M., Shihabuddin L., Hazlett E.A., Buchsbaum M.S. Poor outcome in chronic schizophrenia is associated with progressive loss of volume of the putamen. Schizophrenia Research 2009, 113:241-245.
45. Molina Rodriguez V., Montz Andree R., Perez Castejon M.J., Capdevila Garcia E., Carreras Delgado J.L., Rubia Vila F.J. SPECT study of regional cerebral perfusion in neuroleptic-resistant schizophrenic patients who responded or did not respond to clozapine. American Journal of Psychiatry 1996, 153:1343-1346.
46. Molina V., Gispert J.D., Reig S., Sanz J., Pascau J., Santos A., Palomo T., Desco M. Cerebral metabolism and risperidone treatment in schizophrenia. Schizophrenia Research 2003, 60:1-7.
47. Molina V., Reig S., Sarramea F., Sanz J.F., Artaloytia J., Luque R., Aragüés M., Pascau J., Benito C., Palomo T., Desco M. Anatomical and functional brain variables associated to clozapine response in treatment-resistant schizophrenia. Psychiatry Research: Neuroimaging 2003, 124:153-161.
48. Molina V., Sanz J., Benito C., Palomo T. Direct association between orbitofrontal atrophy and the response of psychotic symptoms to olanzapine in schizophrenia. nternational Clinical Psychopharmacology 2004, 19:221-228.
49. Molina V., Gispert J.D., Reig S., Sanz J., Pascau J., Santos A., Desco M., Palomo T. Cerebral metabolic changes induced by clozapine in schizophrenia. Psychopharmacology 2005, 178:17-26.
50. Molina V., Sanz J., Sarramea F., Luque R., Benito C., Palomo T. Dorsolateral prefrontal and superior temporal volume deficits in first episode psychosis that evolve into schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 2006, 256:106-111.
51. Navari S., Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical review of MRI findings. Psychological Medicine 2009, 39:1763-1777.
52. O'Donnell B.F., Swearer J.M., Smith L.T., Nestor P.G., Shenton M.E., McCarley R.W. Selective deficits in visual perception and recognition in schizophrenia. American Journal of Psychiatry 1996, 153:687-692.
53. Robinson D.G., Woerner M.G., Alvir J.M., Geisler S., Koreen A., Sheitman B., Chakos M., Mayerhoff D., Bilder R., Goldman R., Lieberman J.A. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 1999, 156:544-549.
54. Rodríguez V.M., Andrée R.M., Castejón M.J., Zamora M.L., Alvaro P.C., Delgado J.L., Vila F.J. Fronto-striato-thalamic perfusion and clozapine response in treatment-refractory schizophrenic patients. A 99mTc-HMPAO study. Psychiatry Research: Neuroimaging 1997, 76:51-61.
55. Rossi A., Bustini M., Prosperini P., Marinangeli M.G., Splendiani A., Daneluzzo E., Stratta P. Neuromorphological abnormalities in schizophrenic patients with good and poor outcome. Acta Psychiatrica Scandinavica 2000, 101:161-166.
56. Shenton M.E., Dickey C.C., Frumin M., McCarley R.W. A review of MRI findings in schizophrenia. Schizophenia Research 2001, 49:1-52.
57. Shihabuddin L., Buchsbaum M.S., Hazlett E.A., Haznedar M.M., Harvey P.D., Newman A., Schnur D.B., Spiegel Cohen J., Wei T., Machac J., Knesaurek K., Vallabhajosula S., Biren M.A., Ciaravolo T.M., Luu Hsia C. Dorsal striatal size, shape, and metabolic rate in never-medicated and previously medicated schizophrenics performing a verbal learning task. Archives of General Psychiatry 1998, 55:235-243.
58. Shihabuddin L., Buchsbaum M.S., Hazlett E.A., Silverman J., New A., Brickman A.M., Mitropoulou V., Nunn M., Fleischman M.B., Tang C., Siever L.J. Striatal size and relative glucose metabolic rate in schizotypal personality disorder and schizophrenia. Archives of General Psychiatry 2001, 58:877-884.
59. Tamagaki C., Sedvall G.C., Jonsson E.G., Okugawa G., Hall H., Pauli S., Agartz I. Altered white matter/gray matter proportions in the striatum of patients with schizophrenia: a volumetric MRI study. American Journal of Psychiatry 2005, 162:2315-2321.
60. Tek C., Gold J., Blaxton T., Wilk C., McMahon R.P., Buchanan R.W. Visual perceptual and working memory impairments in schizophrenia. Archives of General Psychiatry 2002, 59:146-153.
61. van Haren N.E., Cahn W., Hulshoff Pol H.E., Schnack H.G., Caspers E., Lemstra A., Sitskoorn M.M., Wiersma D., van den Bosch R.J., Dingemans P.M., Schene A.H., Kahn R.S. Brain volumes as predictor of outcome in recent-onset schizophrenia: a multi-center MRI study. Schizophrenia Research 2003, 64:41-52.
62. van Haren N.E., Hulshoff Pol H.E., Schnack H.G., Cahn W., Mandl R.C., Collins D.L., Evans A.C., Kahn R.S. Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study. Neuropsychopharmacology 2007, 32:2057-2066.
63. Winterer G., Musso F., Beckmann C., Mattay V., Egan M.F., Jones D.W., Callicott J.H., Coppola R., Weinberger D.R. Instability of prefrontal signal processing in schizophrenia. American Journal of Psychiatry 2006, 163:1960-1968.
64. Wright I.C., McGuire P.K., Poline J.B., Travere J.M., Murray R.M., Frith C.D., Frackowiak R.S., Friston K.J. A voxel-based method for the statistical analysis of gray and white matter density applied to schizophrenia. Neuroimage 1995, 2:244-252.